Lenz Therapeutics Inc (LENZ) Stock Price, Quote & News

Company Profile

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, Cal...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7000

Website: www.lenz-tx.com

Address:

201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States

Rmccall Dec. 6 at 9:15 PM

$LENZ someone had to do it!!! The first of many.

1 · Reply

HedgeAlerts Dec. 4 at 7:16 AM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $25.00 Put · DEC 19, 2025 Exp Entry Price: $0.65 - $1.90 Exit Price Target: $1.52 Profit Margin: +134% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Max_Regards Dec. 4 at 3:10 AM

$LENZ on today’s investor meeting $LENZ CEO suggested Wallstreetbets is significantly underestimating the potential here. Feels good hearing him say it outloud.

1 · Reply

SuperGreenToday Dec. 4 at 12:43 AM

$LENZ Share Price: $27.98 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $2.63 – $3.26 Target Zone: $4.30 – $5.25 Potential Upside: 54% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Max_Regards Dec. 3 at 1:17 AM

$LENZ https://ir.lenz-tx.com/news-events/ir-calendar/detail/20251202-piper-sandler-37th-annual-healthcare-conference?utm_source=chatgpt.com Link above is for the Piper Sandler 37rd Annual Healthcare Conference. My biggest take away? They said based on their conservative estimates of 6% market penetration the revenue potential is 6 Billion Dollars. That’s just the US market potential. $6,000,000,000 incase you want to see it typed out! Competitors are coming out 2026 but VIZZ is first to market and Direct To Consumer campaign starts Q1 2026. Competitors are also more similar to Vuity which is bad for them and good for VIZZ. Impacts from the DTC campaign will be 6-10 weeks from its launch. I for one am hyped and if we realize the conservative estimates that’s massive. Time will tell.

2 · Reply

Dreamit2 Dec. 2 at 9:05 PM

$LENZ Anyone listening to the presentation today?

2 · Reply

Max_Regards Dec. 2 at 8:09 PM

$LENZ hold your BUTTS Shorts trying to force a downtrend because they are scared of the hole they have dug! Greedy Pigs!

1 · Reply

WStreetCoffee Dec. 2 at 2:33 PM

$LENZ how is Vizz goin?

1 · Reply

HedgeAlerts Dec. 1 at 10:09 PM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $30.00 Put · DEC 19, 2025 Exp Entry Price: $1.85 - $2.45 Exit Price Target: $3.42 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

AlexSwiss77 Nov. 26 at 9:40 PM

$LENZ excellent holding of 30$ support and move back up in a bullish way

2 · Reply

LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 8:30 AM EST - 6 days ago

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

Nov 25, 2025, 4:05 PM EST - 11 days ago

LENZ Therapeutics to Present at Upcoming Investor Conferences

Nov 5, 2025, 1:21 PM EST - 4 weeks ago

LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:00 AM EST - 4 weeks ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Oct 29, 2025, 8:00 AM EDT - 5 weeks ago

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Sep 30, 2025, 8:05 AM EDT - 2 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 30, 2025, 8:00 AM EDT - 2 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 10, 2025, 3:05 PM EDT - 3 months ago

LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 2:49 PM EDT - 3 months ago

LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 3 months ago

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Jul 31, 2025, 4:05 PM EDT - 4 months ago

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

Jul 31, 2025, 9:10 AM EDT - 4 months ago

Lenz (LENZ) Q2 Revenue Jumps 604%

Jul 30, 2025, 8:00 AM EDT - 4 months ago

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 29, 2025, 1:32 PM EDT - 4 months ago

LENZ Therapeutics: Undervalued Ahead Of PDUFA

Jul 28, 2025, 8:00 AM EDT - 4 months ago

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

Jul 7, 2025, 8:00 AM EDT - 5 months ago

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Jul 1, 2025, 4:23 PM EDT - 5 months ago

LENZ Therapeutics: Presbyopia Eyedrops Look Promising

May 9, 2025, 10:33 AM EDT - 7 months ago

LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:03 AM EDT - 7 months ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 7, 2025, 4:05 PM EDT - 7 months ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 4:30 PM EDT - 7 months ago

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

Apr 30, 2025, 4:30 PM EDT - 7 months ago

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Apr 7, 2025, 8:00 AM EDT - 8 months ago

LENZ Therapeutics: Freedom From Reading Glasses

Mar 27, 2025, 5:33 PM EDT - 9 months ago

LENZ Therapeutics Stock Is Attractive Before PDUFA

Mar 19, 2025, 8:09 PM EDT - 9 months ago

LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 4:05 PM EDT - 9 months ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 11, 2025, 8:00 AM EDT - 9 months ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

Mar 3, 2025, 8:00 AM EST - 9 months ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025

Feb 24, 2025, 8:00 AM EST - 10 months ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2024, 11:43 AM EST - 1 year ago

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 1:51 PM EDT - 1 year ago

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

Oct 27, 2024, 9:00 PM EDT - 1 year ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Oct 21, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS

Aug 30, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks

Aug 16, 2024, 7:43 PM EDT - 1 year ago

LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Aug 7, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 10, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 11, 2024, 7:26 AM EDT - 1 year ago

LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 1, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Apr 3, 2024, 7:49 AM EDT - 1 year ago

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

Apr 3, 2024, 7:00 AM EDT - 1 year ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Apr 2, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Mar 21, 2024, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

Rmccall Dec. 6 at 9:15 PM

$LENZ someone had to do it!!! The first of many.

1 · Reply

HedgeAlerts Dec. 4 at 7:16 AM

0 · Reply

Max_Regards Dec. 4 at 3:10 AM

$LENZ on today’s investor meeting $LENZ CEO suggested Wallstreetbets is significantly underestimating the potential here. Feels good hearing him say it outloud.

1 · Reply

SuperGreenToday Dec. 4 at 12:43 AM

0 · Reply

Max_Regards Dec. 3 at 1:17 AM

2 · Reply

Dreamit2 Dec. 2 at 9:05 PM

$LENZ Anyone listening to the presentation today?

2 · Reply

Max_Regards Dec. 2 at 8:09 PM

$LENZ hold your BUTTS Shorts trying to force a downtrend because they are scared of the hole they have dug! Greedy Pigs!

1 · Reply

WStreetCoffee Dec. 2 at 2:33 PM

$LENZ how is Vizz goin?

1 · Reply

HedgeAlerts Dec. 1 at 10:09 PM

0 · Reply

AlexSwiss77 Nov. 26 at 9:40 PM

$LENZ excellent holding of 30$ support and move back up in a bullish way

2 · Reply

HedgeAlerts Nov. 26 at 2:24 AM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $25.00 Put · DEC 19, 2025 Exp Entry Price: $0.80 - $4.48 Exit Price Target: $7.80 Profit Margin: +74% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Max_Regards Nov. 25 at 10:29 PM

$LENZ LENZ to participate in multiple investor conferences first week of December. Piper Sandler 37th Annual Healthcare Conference Date: December 2, 2025 Location: New York City, NY Format: Fireside chat at 3:30pm ET (live audio webcast) and 1x1 investor meetings 8th Annual Evercore Healthcare Conference Date: December 3, 2025 Location: Coral Gables, FL Format: Fireside chat at 1:20pm ET (live audio webcast) and 1x1 investor meetings Citi’s 2025 Global Healthcare Conference Date: December 4, 2025 Location: Miami, FL Format: Fireside chat at 10:30am ET (live audio webcast) and 1x1 investor meetings

1 · Reply

HedgeAlerts Nov. 25 at 2:25 AM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $30.00 Put · DEC 19, 2025 Exp Entry Price: $2.00 - $2.25 Exit Price Target: $4.22 Profit Margin: +111% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

AlexSwiss77 Nov. 24 at 9:21 PM

$LENZ this reversal is getting really Bullish

1 · Reply

HedgeAlerts Nov. 23 at 3:47 AM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $25.00 Put · DEC 19, 2025 Exp Entry Price: $4.48 - $4.90 Exit Price Target: $7.17 Profit Margin: +60% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 21 at 11:10 PM

0 · Reply

Itinerant Nov. 21 at 6:53 PM

$LENZ I am thinking that this company might be over valued in the near term, but the proof will be in the scripts and the margin, etc. I will wait a bit. International expansion would be a huge thing for valuation.

3 · Reply

HedgeAlerts Nov. 20 at 11:21 PM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $25.00 Put · DEC 19, 2025 Exp Entry Price: $2.50 - $4.48 Exit Price Target: $8.92 Profit Margin: +99% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Max_Regards Nov. 20 at 2:57 PM

$LENZ would love an update soon on how Nov prescriptions are going.

1 · Reply

HedgeAlerts Nov. 20 at 7:23 AM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $25.00 Put · DEC 19, 2025 Exp Entry Price: $4.48 - $4.70 Exit Price Target: $7.35 Profit Margin: +64% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 19 at 9:10 PM

Hedge Alert Live - Protect Your Portfolio Contract: $LENZ $25.00 Put · DEC 19, 2025 Exp Entry Price: $2.80 - $4.48 Exit Price Target: $7.03 Profit Margin: +57% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Max_Regards Nov. 19 at 6:21 PM

$LENZ really good traction lately. Love the buying pressure. Short interest is still high so assuming numbers keep impressing we have a long way up we can go.

0 · Reply

Market Cap	836.07M
Revenue (ttm)	0.00
Net Income (ttm)	-49.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	396,600
Avg Vol	1,136,888
Day's Range	N/A - N/A
Shares Out	31.29M
Stochastic %K	1%
Beta	0.46
Analysts	Strong Sell
Price Target	$52.57